Akcea Therapeutics has announced the publication of results from the Re-FOCUS study that sought to assess the burden of familial chylomicronemia syndrome (FCS) on patients and the impact of Akcea's proposed drug, volanesorsen, on disease burden.
Akcea Therapeutics has announced the publication of results from the Re-FOCUS study that sought to assess the burden of familial chylomicronemia syndrome (FCS) on patients and the impact of Akcea's proposed drug, volanesorsen, on disease burden.
FCS is an ultra-rare disease caused by impaired function of the enzyme lipoprotein lipase. Because patients with FCS cannot break down chylomicrons, they are at risk for hypertriglyceridemia and acute, potentially fatal pancreatitis. Patients with FCS also report pain, fatigue, and imparted cognition among their physical symptoms. Currently, there is no effective therapy available to treat FCS, and patients must rely on strict dietary regimens to manage their disease, which can impact quality of life. Akcea hopes that its investigational drug, volanesorsen, can modulate multiple symptoms of the syndrome.
The new study, reported in Expert Review of Cardiovascular Therapy, was a retrospective, global, web-based survey of patients with FCS (n = 22) who received volanesorsen for 3 or more months during the APPROACH OLE study of volanesorsen for the treatment of FCS. The survey asked about patients’ experiences before and after treatment, and used a 7-point scale (on which 1 registered strong disagreement and 7 registered strong agreement) to assess patients’ perceptions and experiences.
In assessing responses, the researchers found that more patients felt that their strategies for managing their disease were effective after treatment with volanesorsen than before (40% versus 19%), and more patients felt their symptoms were well controlled with adherence to diet after treatment than before (90% versus 55%).
Patients also reported that the number of symptoms they experienced decreased with treatment; the median number of symptoms experienced was 6.5 (interquartile range [IQR], 2.0-13.0) prior to therapy, and 3.5 (IQR, 1.5-6.5) after 3 months of treatment. Patients reported reductions in the incidence of pancreatic pain, steatorrhea, physical weakness, fatigue, and back pain. Among emotional symptoms, patients reported a reduction in feelings of worry, being out of control, and anger or frustration.
When asked how much FCS impacted personal, social, and professional life, 5% of patients reported no interference from the disease before treatment, but that proportion increased to 23% after therapy. The number of patients who reported a high level of interference decreased from 59% prior to treatment to 37% after treatment, and participation in household and personal activities improved with therapy.
According to Michael W. Stevenson, RPh, PhD, global vice president of medical affairs at Akcea, “This landmark study represents an important step in our efforts to identify and quantify the many ways that FCS can affect the physical, functional and emotional health of people living with FCS. The Re-FOCUS study provides helpful, new information as we work to design and validate a tool that can accurately evaluate changes in disease burden with therapeutic intervention.”
Reference
Arca M, Hsieh A, Soran H, Rosenblit P, O’Dea L, Stevenson M. The effect of volanesoren treatment on the burden associated with familial chylomicronemia Syndrome: the results of the ReFOCUS study. [Published online June 11, 2018.] Expert Rev Cardiovasc Ther. doi: 0.1080/14779072.2018.1487290.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More